Latest News & Features
Big Pharma
Inter partes review challenges broad claims and monopolisation over mRNA tech amidst existing legal dispute | Alnylam set to appeal separate court ruling against Moderna. 29 August 2023
Big Pharma
Bernie Sanders’ plan to ‘delink’ the price of drugs from the cost of development ignores history, argue Andrei Iancu and David Kappos. 29 August 2023
Big Pharma
Payments mark the sixth and seventh made to resolve price-fixing charges | Teva donates $50 million in drugs to humanitarian organisations. 24 August 2023
Big Pharma
Indian drugmaker had challenged PTAB decision that patent for new version of ruxolitinib was invalid as obvious | Decision hands a victory to US rival. 24 August 2023
Big Pharma
Biologics patent attorney aims to strengthen the firm’s global patent networks. 22 August 2023
Big Pharma
The pharmaceutical company agreed to pay millions to resolve a multi-district antitrust suit brought by more than 40 US state attorneys | Company sued over alleged actions aimed at preserving the monopoly of anti-addiction drug. 22 August 2023
Big Pharma
UPC announces public hearings at Munich court | Proceedings relate to the dispute over patents covering the in-situ detection of analytes. 22 August 2023
Americas
A recent precedential case highlights the thorny issue of what constitutes a fair response to new claim constructions following an institution, says Blair Jacobs of McKool Smith. 17 August 2023
Biotechnology
Judges uphold PTAB decision invalidating Incept patents related to use of biodegradable filler in radiation treatment | Swedish firm Palette had challenged patents through inter partes review. 17 August 2023
Big Pharma
This week marks the first anniversary of its enactment but the US Inflation Reduction Act still poses questions for pharmaceutical companies, say Alice Valder Curran and Cullen Taylor of Hogan Lovells. 15 August 2023